To determine if p38 activity is required for PTK6 shRNA-induced apoptosis of ER+ breast cancer cells, we treated PTK6 shRNA-expressing cells with SB203580, a p38 MAPK inhibitor. This evidence concerns the gene PTK6 and breast carcinoma.